VOL 2, N°18 - NOVEMBER 2017 NEWSLETTER

The latest scientific research on Alzheimer • Frailty/Sarcopenia • Nutrition • Nursing Home •

aging-news.net

10th Clinical Trials on Alzheimer's Disease (CTAD)

Development of the next generation of Alzheimer's disease drugs is currently presented in Boston see:

CTAD2017 program

CTAD 10th Conference on Clinical Trials in Alzheimer's Disease

Abstracts are available.

See more

CTAD 2017 Statistical workshop: Estimands and primary analyses in AD clinical trials

The primary objective of a clinical trial should be clearly defined with regard to the target of estimation (estimand) for the efficacy of an investigational drug. The fully specified treatment effect of interest should then determine the data collection, data anlysis, handling of missing data, and other trial design elements.

See more

Clinical evaluation of 18F-Pl-2620, a next generation tau pet agent in subjects with alzheimer's disease and progressive supranuclear palsy

Intracellular tau deposition is a key pathologic feature of alzheimer's disease (AD) and other neurodegenerative disorders. Several positron emission tomography tau probes have been developed for in vivo detection of brain tau load, although quantification is challenging due to high off target binding and slow kinetics.

See more

Congress Agenda

International Academy on Nutrition & Aging (during ICFSR 2018)

March 1-2-3, 2018, Miami, USA

More information

ICFSR International Conference on Frailty Sarcopenia Research

March 1-2-3, 2018, Miami, USA For oral communication and poster call for abstracts: deadline November 19, 2017

More information

Click here to send them an invitation to receive it

Aging News SERDI PUBLISHER aging-news@aging-news.eu